Percutaneous or transapical aortic valve replacement under non-extracorporeal circulation is a great advancement in cardiovascular surgery in recent years and can benefit those patients with severe aortic stenosis. This procedure was started in 2002 and is now being used in clinical cases abroad. The safety of the procedure is high and the mortality associated with the procedure has decreased significantly, making it an optimal procedure to save patients with severe aortic stenosis. There are three main approaches to interventional aortic valve replacement: the prograde approach (transvenous puncture of the interatrial septum via the left atrium-micuspid valve-left ventricle pathway), the retrograde approach (femoral artery-aortic pathway), and the transapical approach. The retrograde and transapical approaches are currently the most commonly used. The retrograde approach does not require a chest opening and delivers the valve through the peripheral artery (femoral or common carotid) to the aortic valve position; however, this approach has significant disadvantages: the delivery path is long and cannot be used if the patient has severe calcification and stenosis of the peripheral artery or abdominal aorta. In contrast, the transapical approach involves only a small incision in the left anterior chest and delivery of the valve to the aortic valve position through an apical puncture. The advantages of the transapical approach are that it is easy, fast, accurate, and not limited by peripheral vascular pathology. Interventional aortic valves are now relatively well developed, are biologic valves, and have been clinically proven to have good durability. They are mainly suitable for patients with symptomatic severe aortic stenosis (orifice area < 1 cm2 ), high risk for conventional surgery, advanced age (>70-75 years), and severe comorbidities that preclude surgical intervention. As this technique continues to mature, its indications will continue to expand, bringing benefits to patients with aortic valve lesions.